ストックスクリーナーアプリを入手
4.09
1.57%
-0.06
Mannkind Corp (MNKD) 最新ニュース
MannKind Corporation Submits Prospectus Supplement with Legal Opinion on Common Stock Offering - Kalkine Media
MannKind (NASDAQ: MNKD) resale taps $0.01 warrant shares - Stock Titan
MannKind files legal opinion for common stock offering under shelf registration - TradingView
MNKD Stock Jumps On Receiving FDA Approval For Afrezza To Treat Diabetes In Children - Stocktwits
MNKD Stock Heads For Strongest Month In Over Three Years As FDA Catalyst Draws Closer - Stocktwits
MannKind Stock Plummets After Partner United Therapeutics Unveils New ‘Category Killer Product’ - Stocktwits
How MannKind’s (MNKD) Rising Revenue but Renewed Losses Could Reshape Its Growth Investment Story - simplywall.st
Mannkind Stock Price Forecast. Should You Buy MNKD? - StockInvest.us
Rubric Capital discloses 5.83% MannKind Corporation (MNKD) stake - Stock Titan
Research Analysts Set Expectations for MannKind Q3 Earnings - MarketBeat
MNKD Stock Price, Quote & Chart - ChartMill
MannKind FY2029 EPS Estimate Decreased by HC Wainwright - MarketBeat
MannKind gains FDA approvals, boosting growth p... - Pluang
MannKind Announces FDA Approval of Furoscix ReadyFlow™, the First and Only Autoinjector Delivering IV-Equivalent Diuretic Therapy for the Treatment of Edema in Adults with Heart Failure or Chronic Kidney Disease - Taiwan News
Mannkind director Steven Binder sells $158,547 in common stock By Investing.com - Investing.com UK
MannKind Corp (MNKD) Director Steven Binder Sells 39,051 Shares - GuruFocus
Mannkind director Steven Binder sells $158,547 in common stock - Investing.com India
Steven Binder Sells 39,051 Shares of MannKind (NASDAQ:MNKD) Stock - MarketBeat
Sei Investments Co. Buys 253,537 Shares of MannKind Corporation $MNKD - MarketBeat
First Trust Advisors LP Raises Stake in MannKind Corporation $MNKD - MarketBeat
Dimensional Fund Advisors LP Acquires 509,692 Shares of MannKind Corporation $MNKD - marketbeat.com
MannKind (NASDAQ:MNKD) Rating Lowered to Sell at Wall Street Zen - MarketBeat
MannKind (MNKD) insider Steven Binder plans 39,051-share Rule 144 stock sale - Stock Titan
Danbury biopharma company expands workforce, manufacturing amid new product launches - Hartford Business Journal
MannKind (NASDAQ:MNKD) Upgraded by Zacks Research to Hold Rating - MarketBeat
Empowered Funds LLC Invests $1.88 Million in MannKind Corporation $MNKD - MarketBeat
H.C. Wainwright reiterates Buy rating on MannKind stock at $10 By Investing.com - Investing.com South Africa
MNKD Maintained by Wells Fargo -- Price Target Lowered to $13.00 - GuruFocus
MannKind's Diversified Portfolio Seen Leading to Higher Revenue in H2, Wedbush Says - Yahoo Finance
H.C. Wainwright reiterates Buy rating on MannKind stock at $10 - Investing.com
MannKind Corp (MNKD) (Q2 2026) Earnings Call Highlights: Record Revenue and Major Catalysts Drive Growth - GuruFocus
MannKind Q2 Earnings Call Highlights - marketbeat.com
MNKD SWOT Analysis: Financial Challenges and Growth Potential Re - GuruFocus
MannKind (NASDAQ:MNKD) Announces Quarterly Earnings Results - MarketBeat
Earnings call transcript: MannKind tops revenue forecast in Q2 2026 By Investing.com - Investing.com Nigeria
Earnings call transcript: MannKind tops revenue forecast in Q2 2026 - Investing.com
Is MannKind Corp (MNKD) Positioned for Growth After Q2 Earnings? - GuruFocus
MannKind Q2 2026 slides: revenue surges 43%, marketed products lead - Investing.com
Compared to Estimates, MannKind (MNKD) Q2 Earnings: A Look at Key Metrics - Yahoo Finance
MannKind (MNKD) Reports Q2 Loss, Beats Revenue Estimates - Yahoo Finance
MannKind: Q2 Earnings Snapshot - Barchart.com
MannKind Corp Q2 2026: Revenue $109.4M, EPS $(0.06) — 10-Q Summary - TradingView
MannKind (NASDAQ: MNKD) posts $199M H1 2026 revenue after scPharma deal - Stock Titan
MannKind Reports Second Quarter 2026 Financial Results and Provides Business Update - Yahoo Finance
MannKind earnings in focus after FUROSCIX ReadyFlow approval By Investing.com - Investing.com Nigeria
MannKind Corp expected to post breakeven results a shareEarnings Preview - TradingView
MannKind Corp (MNKD) Valuation: PE, PB & Fair Value Analysis - TradingKey
MannKind Reports Positive Topline Results from Phase 1b INFLO-1 Study of Nintedanib Dry Powder Inhalation in Idiopathic Pulmonary Fibrosis - Quiver Quantitative
MannKind Reports Positive Phase 1b INFLO-1 Results, Demonstrating Safety and Tolerability of Nintedanib DPI and Clinical Validation of Its DPI Technology in IPF - GlobeNewswire
MannKind’s Inhaled IPF Drug Clears Phase 1b Safety Hurdle, Phase 2 Underway - Yahoo Finance
MannKind will review second-quarter results in Aug. 5 webcast - Stock Titan
FDA Approves Mannkind's At-Home Treatment Option for Heart Failure or Kidney Disease - Yahoo Finance
MannKind Corp (MNKD) Shareholder Structure: Major Shareholders & Institutional Holdings - TradingKey
1.35%
0.62%
大文字化:
|
ボリューム (24 時間):